5,477
edits
Semaglutide and cardiovascular risk: Difference between revisions
no edit summary
No edit summary |
No edit summary |
||
| Line 69: | Line 69: | ||
</div> | </div> | ||
[[File: | [[File:Obesity-waist circumference.svg|thumb|right|300px|[[Waist circumference]], [[central obesity]], and [[visceral fat]] are strongly related to cardiometabolic risk.]] | ||
[[File: | [[File:Sleep-150.png|thumb|left|220px|[[Sleep apnea]] can worsen cardiovascular risk; W8MD can arrange convenient [[home sleep study]] testing when appropriate.]] | ||
==Overview== | ==Overview== | ||
| Line 135: | Line 135: | ||
* [[Stroke]] | * [[Stroke]] | ||
{{div col end}} | {{div col end}} | ||
[[File:W8MD-Team.jpg|thumb|right|350px|[[W8MD Weight Loss, Sleep and MedSpa]] helps patients with semaglutide evaluation, cardiovascular-risk focused weight loss, nutrition, sleep apnea screening, and long-term maintenance.]] | |||
[[File:Woman-losing-weight.jpeg|thumb|right|350px|Cardiovascular risk reduction with semaglutide works best when medication is combined with nutrition, physical activity, blood pressure control, sleep optimization, and medical follow-up.]] | |||
[[File:Before-and-after-weight-loss.jpeg|thumb|right|350px|Before-and-after weight loss image. Individual semaglutide and cardiovascular-risk outcomes vary and require medical supervision.]] | |||
This cluster is increasingly described as cardiovascular-kidney-metabolic risk. A patient’s cardiovascular risk is not just a number on a scale. It includes body weight, waist circumference, blood pressure, cholesterol, glucose, sleep apnea, kidney function, family history, smoking status, activity level, medications, and prior cardiovascular events. | This cluster is increasingly described as cardiovascular-kidney-metabolic risk. A patient’s cardiovascular risk is not just a number on a scale. It includes body weight, waist circumference, blood pressure, cholesterol, glucose, sleep apnea, kidney function, family history, smoking status, activity level, medications, and prior cardiovascular events. | ||
| Line 237: | Line 239: | ||
==Semaglutide and stroke risk== | ==Semaglutide and stroke risk== | ||
[[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" /> | [[Stroke]] risk is increased by hypertension, diabetes, smoking, atrial fibrillation, obesity, sleep apnea, and atherosclerotic disease. Semaglutide’s SELECT benefit included nonfatal stroke as part of the composite endpoint.<ref name="SELECT" /> | ||